NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/05/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization391.23 mln
Float33.90 mln
Earnings Date07/30/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
2.5
Highly suspicious
1-Year Forecast
8.81
Transformational upside
Relative Strength
82
/ 100
Strongly outperforming
Debt / Equity
0.40
Low leverage
ROE
-90.50
Deeply negative
Business Description
Autolus Therapeutics is a UK-based biopharmaceutical company focused on developing advanced T cell therapies to treat various cancers and autoimmune conditions. Its leading program, obecabtagene autoleucel, targets a protein called CD19 and is currently being tested in clinical trials for certain types of leukemia in both adults and children. The company has several other therapies in development aimed at treating conditions such as lymphoma, neuroblastoma, and multiple myeloma. Founded in 2014 and headquartered in London, Autolus operates across multiple international markets.
